Aigh Capital Management LLC Annovis Bio, Inc. Transaction History

Aigh Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$9.37 - $14.12 $3.47 Million - $5.23 Million	-370,129 Reduced 88.32%	48,941 $464,000
Q2 2023 Aug 14, 2023	BUY	$11.95 - $16.31 $5.01 Million - $6.84 Million	419,070 New	419,070 $5.99 Million
Q4 2021 Feb 10, 2022	SELL	$17.58 - $37.67 $1.17 Million - $2.5 Million	-66,469 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$30.95 - $120.97 $1.86 Million - $7.26 Million	-60,000 Reduced 47.44%	66,469 $2.11 Million
Q2 2021 Aug 12, 2021	BUY	$21.55 - $96.1 $198,540 - $885,369	9,213 Added 7.86%	126,469 $10.8 Million

Q1 2021 May 13, 2021	SELL	$8.15 - $38.44 $2.82 Million - $13.3 Million	-346,541 Reduced 74.72%	117,256 $3.1 Million
Q4 2020 Feb 16, 2021	BUY	$4.36 - $7.54 $2.02 Million - $3.5 Million	463,797 New	463,797 $3.5 Million

1.2M

779K

1.77M

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $47M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Aigh Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aigh Capital Management LLC with notifications on news.